J.P. Morgan Keeps Their Sell Rating on Owens & Minor (OMI)
UBS Maintains Owens & Minor(OMI.US) With Buy Rating, Cuts Target Price to $25
A Quick Look at Today's Ratings for Owens & Minor(OMI.US), With a Forecast Between $12.5 to $18.5
Owens & Minor Is Maintained at Neutral by Baird
Owens & Minor Price Target Cut to $14.00/Share From $19.00 by Baird
Owens & Minor Analyst Ratings
Barclays Sticks to Their Hold Rating for Owens & Minor (OMI)
Hold Rating Maintained for Owens & Minor Amid Mixed Performance and Ongoing Challenges
Barclays Maintains Owens & Minor(OMI.US) With Hold Rating, Maintains Target Price $18
Baird Maintains Owens & Minor(OMI.US) With Hold Rating, Maintains Target Price $19
Owens & Minor Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX), Denali Therapeutics (DNLI) and Owens & Minor (OMI)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Merus (MRUS), Twist Bioscience (TWST) and Owens & Minor (OMI)
Owens & Minor Analyst Ratings
Barclays Maintains Equal-Weight on Owens & Minor, Lowers Price Target to $18
Barclays Maintains Owens & Minor(OMI.US) With Hold Rating, Maintains Target Price $18
Analysts Conflicted on These Healthcare Names: Owens & Minor (OMI), Tandem Diabetes Care (TNDM) and Alignment Healthcare (ALHC)
Analysts Conflicted on These Healthcare Names: Aquestive Therapeutics (AQST), Eli Lilly & Co (LLY) and Owens & Minor (OMI)
Market Perform Rating Maintained for Owens & Minor Amid Strategic Acquisitions and Financial Caution
Citi Maintains Owens & Minor(OMI.US) With Buy Rating